CAPcasts
HER2 Testing and Clinical Decision Making in GEA
9:51
The 2026 guideline, “HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma Update” addresses tumor heterogeneity, variable specimen quality, and evolving testing approaches, reflecting advances in testing since 2016.
Three strong recommendations and four statements reaffirmed as good practice statements are available for review as an early online release in the Archives…